Central Serous Chorioretinopathy Treatments: A Mini Review

Pierluigi Iacono, Maurizio Battaglia Parodi, Bruno Falcomatà, Francesco Bandello

Research output: Contribution to journalArticlepeer-review


Central serous chorioretinopathy (CSC) is a retinal disorder that primarily affects young (20- to 50-year-old) white men, although it is seen occasionally in older patients and females. CSC is characterized by avascular focal leakage through the retinal pigment epithelium (RPE), resulting in serous detachment of the neurosensory retina. The course is usually self-limiting and in most cases resolves spontaneously within a 3-month period, with visual acuity usually recovering to 20/30 or better. However, chronic CSC may develop as a consequence of recurrences or persistent neurosensory detachment, and can result in progressive RPE atrophy and permanent visual loss. A primary involvement of the RPE and choroidal vascularization play a significant role in the pathogenesis of CSC and the current treatment options attempt to restore the functions of the RPE and the normal choroidal vasculature. The aim of the current review is to provide an overview of the current therapeutical approaches to CSC, including observation, laser treatment, photodynamic therapy with verteporfin, intravitreal anti-vascular endothelial growth factor therapy and the mineralocorticoid receptor antagonists.

Original languageEnglish
Pages (from-to)76-83
Number of pages8
JournalOphthalmic Research
Issue number2
Publication statusPublished - Jan 1 2016


  • Anti-vascular endothelial growth factor
  • Central serous chorioretinopathy
  • Laser treatment
  • Mineralocorticoid antagonists
  • Photodynamic therapy

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Central Serous Chorioretinopathy Treatments: A Mini Review'. Together they form a unique fingerprint.

Cite this